ICKSH 2023
2023 KOREAN SOCIETY OF HEMATOLOGY INTERNATIONAL CONFERENCE
& 64th ANNUAL MEETING
March 31 - April 2, 2022
Grand Walkerhill Hotel, Seoul, Korea
Martina U. MuckenthalerPL01Regulation of iron metabolismUniversity of Heidelberg, GermanyCVAbstract
Marcel van den BrinkPL02The role of the intestinal microbiome in cancer immunotherapyMemorial Sloan Kettering Cancer Center, USACVAbstract
Toshio SudaPL03Recent advance in the hematopoietic stem cell researchNational University of Singapore, SingaporeCVAbstract
Taeghwan HyeonPS01What can Nano do for Medicine?Seoul National University, KoreaCVAbstract
Chiaki NakasekoJS01-1POEMS syndrome: advances in molecular pathophysiology and treatmentInternational University of Health and Welfare School of Medicine, JapanCVAbstract
Jin Seok KimJS01-2Updates on POEMS syndrome in KoreaYonsei University College of Medicine, KoreaCVAbstract
Hiroshi HandaJS01-3Therapeutic approach of Waldenström's macroglobulinemia in JapanGunma University, JapanCVAbstract
Hosup LeeJS01-4Clinical researches on Waldenström's macroglobulinemia in KoreaKosin University College of Medicine, KoreaCVAbstract
Katy RezvaniJS02-1NK cells: next generation cell therapies for cancerThe University of Texas MD Anderson Cancer Center, USACVAbstract
Seok Jin KimJS02-2Treatment of extranodal NK/T-cell lymphoma: Korean Lymphoma Working Party experienceSungkyunkwan University School of Medicine, KoreaCVAbstract
John DiPersioJS02-3CART for the treatment of T cell malignanciesWashington University School of Medicine, USACVAbstract
Deok-Hwan YangJS02-4Treatment of peripheral T-cell lymphoma: Korean Lymphoma Working Party experienceChonnam National University Medical School, KoreaCVAbstract
Uwe PlatzbeckerJS03-1Novel approaches in MDSLeipzig University Hospital, GermanyCVAbstract
June-Won CheongJS03-2Treatment of MDS: Korean AML/MDS working party experienceYonsei University College of Medicine, KoreaCVAbstract
Lionel AdèsJS03-3Standard management of MDSHopital Saint Louis and Paris University, FranceCVAbstract
Yoo-Jin KimJS03-4Genetic alterations in myelodysplastic neoplasmsThe Catholic University of Korea, KoreaCVAbstract
Nguyen Thi ThaoJS04-1Overview of AA diagnosis and treatment in NIHBT, VietNamNational Institute of Hematology and Blood Transfusion, VietnamCVAbstract
Lalita NorasetthadaJS04-2The incidence and real-world outcome of aplastic anemia in ThailandChiang Mai University, ThailandCVAbstract
Jun Ho JangJS04-3Role of TPO receptor agonists in aplastic anemia treatmentSamsung Medical Center, KoreaCVAbstract
Mahmood A. ChowdhuryJS05-1Overview of thalassaemia and hemoglobinopathies in BangladeshChattogram Maa-O-Shishu Hospital Medical College, BangladeshCVAbstract
Chean SophalJS05-2Current situation of thalassemia care in CambodiaNational Pediatric Hospital, CambodiaCVAbstract
Heewon ChuehJS05-3Epidemiology and diagnosis of hemolytic anemia in KoreaDong-A University College of Medicine, KoreaCVAbstract
Geoffrey McDermottCS01-1Accelerate breakthroughs in hematology with single cell sequencing10x Genomics, Inc., USACVAbstract
Tabe YokoCS01-2AI technology in the field of blood diseaseJuntendo University, JapanCVAbstract
Gina SunCS01-3Discover the unique power of using droplet digital PCR (ddPCR) for hematology-oncology applicationsBio-Rad Laboratories, USACVAbstract
Yongkeun ParkCS01-4Holotomography and artificial intelligence: label-free 3D imaging, classification, and inferenceTomocube Inc., KoreaCVAbstract
Bong-Seog KimCS02-1A Phase 1a Study of BR101801, PI3Kγδ and DNA PK Triple Inhibitor, in Adult Patients with Advanced Hematologic MalignanciesBoryung Co. Ltd., KoreaCVAbstract
Woorim KangCS02-2The gut microbiome as a novel predictive biomarker and therapeutic target in lymphoma patientsCJ Bioscience Inc., KoreaCVAbstract
Jonghwa WonCS02-3Bispecific antibody : ABL BioABL Bio Inc., KoreaCVAbstract
Sung-Min AhnCS02-4KF1601, a novel orally bioavailable inhibitor of Bcr-Abl T315I, without thrombotic microangiopathyImmunoForge Inc., KoreaCVAbstract
Kelly WalkovichSS01-1How to diagnosis and treat neutropenia in childhoodUniversity of Michigan, USACVAbstract
Keon Hee YooSS01-2Updates in the treatment of pediatric relapsed/refractory acute myeloid leukemiaSungkyunkwan University School of Medicine, KoreaCVAbstract
Micheal VernerisSS01-3Use of chimeric antigen receptor (CAR) expressing T cells for acute lymphoblastic leukemia (ALL)Children’s Hospital Colorado, USACVAbstract
Ralf KüppersSS02-1Pathogenesis of hodgkin lymphomaUniversity of Duisburg-Essen, GermanyCVAbstract
Natalie S GroverSS02-2Emerging cellular therapy in HLThe University of North Carolina at Chapel Hill, USACVAbstract
Hyeon-Seok EomSS02-3Novel treatment of relapsed/refractory hodgkin lymphomaNational Cancer Center, KoreaCVAbstract
Emma M. GroarkeSS03-1Aplastic anemia: Current management considerationsNational Institutes of Health, USACVAbstract
Jaroslaw P. MaciejewskiSS03-2Clinical and molecular factors of clonal evolution in aplastic anemiaCleveland Clinic, USACVAbstract
Jae Wook LeeSS03-3Non-transplant therapy for pediatric aplastic anemiaThe Catholic University of Korea, KoreaCVAbstract
Sandro RossettiSS04-1Diagnosis and treatment of TA-TMA; Current challenge and future strategiesHospital Alexion Pharmaceuticals, Inc., USACV
Kathleen FresonSS04-2Genetics of inherited thrombocytopeniaUniversity of Leuven, BelgiumCVAbstract
Hyun Kyung KimSS04-3Advances on pathogenesis and diagnosis of TTPSeoul National University College of Medicine, KoreaCVAbstract
Roni ShouvalSS05-1Artificial intelligence in hematology: basic conceptsMemorial Sloan kettering Cancer Center, USACVAbstract
Valeria VisconteSS05-2How ML deepens our understanding of hematologic malignancies?Cleveland Clinic, USACVAbstract
Jongmun ChoiSS05-3Pitfalls of AI for medical applicationGreen Cross Genome, KoreaCVAbstract
Niels van de DonkSS06-1Identification of high-risk multiple myelomaAmsterdam University Medical Center, The NetherlandsCVAbstract
Sung-Hoon JungSS06-2Updated diagnosis and treatment of plasma cell leukemiaChonnam National University Hwasun Hospital, KoreaCVAbstract
Moshe GattSS06-3Safety and efficacy of locally produced novel BCMA CART cells for relapsed/refractory multiple myeloma and al amyloidosisThe Hebrew University of Jerusalem, IsraelCVAbstract
Yvonne ChenSS07-1Engineering next-generation T cells for cancer immunotherapyUniversity of California, USACVAbstract
Hyoung Jin KangSS07-2Development of CAR-T therapy for acute lymphoblastic leukemiaSeoul National University College of Medicine, KoreaCVAbstract
Hiroshi FujiwaraSS07-3Updates on the latest developments in CAR-T therapiesMie University, JapanCVAbstract
Jill JohnsenSS08-1Genotyping of hemophilia, why we need it and how we do?Division of Hematology University of Washington, USACVAbstract
Jung Woo Han SS08-2Value of national cohort registry data of hemophiliaYonsei University College of Medicine, KoreaCVAbstract
Sang Hyuk ParkSS08-3Essentials of laboratory issues in EmicizumabUlsan University HospitalCVAbstract
Naval DaverSS09-1Immune checkpoint inhibition for AML ; CD47 blockade and beyondMD Anderson Cancer Center, USACV
Miriam Y KimSS09-2Determining the barriers to successful CAR T cell therapy for AMLUniversity of Washington, USACVAbstract
Byung Sik ChoSS09-3Adoptive T cell transfer of three universal tumor associated antigens-specific T cells for the treatment of AMLThe Catholic University of Korea, KoreaCVAbstract
Aly KarsanSS10-1A transcriptomic approach to clinical diagnosis, prognosis and therapy selection in AMLUniversity of British Columbia, CanadaCVAbstract
Sunghoon KwonSS10-2Whole genome sequencing of fluorescence in situ hybridized cells in hematologic malignancies using SLACSSeoul National University, KoreaCVAbstract
Alexander HoischenSS10-3Next generation cytogenetics – optical mapping for comprehensive structural variant detection in hematological malignancies and beyondRadboud University Medical Center, The NetherlandsCVAbstract
Iwijn De VlaminckSS11-1Cell-free DNA profiling for monitoring of complications of hematopoietic cell transplantationCornell University, USACVAbstract
Charles GawadSS11-2Microbial cell-free DNA sequencing to predict bloodstream infection in pediatric cancer patientsStanford University, USACVAbstract
Seung-Tae LeeSS11-3Clinical applications of circulating tumor DNA analysis in lymphomaYonsei University College of Medicine, KoreaCVAbstract
Robin FoaSS12-1Are we moving towards a chemo- and transplant-free management of Ph-positive adult ALL?Sapienza University of Rome, ItalyCVAbstract
Saar I GillSS12-2Development of more-effective CAR T-cell therapy for ALLUniversity of Pennsylvania School of Medicine, USACVAbstract
Jae-Ho YoonSS12-3Overcoming high-risk features in adult ALL patientsThe Catholic University of Korea, KoreaCVAbstract
William J. GreenleafSS13-1Single cell HSPC mapStanford University, USACVAbstract
Kyung-Rok YuSS13-2Humanized mouse and non-human primate: Animal models for hematopoietic stem cell researchSeoul National University, KoreaCVAbstract
Xinxin HuangSS13-3What we know about HSC homing?Fudan University, ChinaCVAbstract
Richard RosenquistSS14-1Translating scientific advances in CLLKarolinska Institute, SwedenCVAbstract
Jennifer R. BrownSS14-2Patient selection for time limited versus continued therapyDana-Farber Cancer Institute, USACVAbstract
Ki-Seong EomSS14-3MRD monitoring in CLL PatientsThe Catholic University of Korea, KoreaCVAbstract
Eun-Ji ChoiES01-1Asciminib: the first-in-class allosteric inhibitor of BCR/ABL1 kinaseUniversity of Ulsan College of Medicine, KoreaCVAbstract
Jieun UhmES01-2Treatment after failure of frontline therapy of CML-CP including allo-HSCTHanyang University College of Medicine, KoreaCV
Jae Joon HanES01-3Update on treatment free remissionKyung Hee University College of Medicine, KoreaCVAbstract
Youngwoo JeonES02-1Intravascular B-cell lymphomaThe Catholic University of Korea, KoreaCV
Jae-Cheol JoES02-2T-large granular lymphocytic leukemiaUniversity of Ulsan College of Medicine, KoreaCVAbstract
Jeong-Ok LeeES02-3Lymphomatoid granulomatosisSeoul National University Bundang Hospital, KoreaCV
Hyewon LeeES03-1Sezary syndrome and mycosis fungoidesNational Cancer Center, KoreaCVAbstract
Hyun Jung LeeES03-2Systemic mastocytosisKyung Hee University College of Medicine, KoreaCVAbstract
Yoo Jin LeeES03-3Plasmacytoid dendritic cell neoplasmUniversity of Ulsan College of Medicine, KoreaCVAbstract
Dong Wook JekarlES04-1Transfusion support for HSCTThe Catholic University of Korea, KoreaCVAbstract
Dae-Hyun KoES04-2Evidence based transfusion thresholdUniversity of Ulsan College of Medicine, KoreaCVAbstract
Eun Jung BaekES04-3Current status of manufactured blood cellsHanyang University College of Medicine, KoreaCVAbstract
Ja Min ByunES05-1Setting up the facility for CAR T cell therapySeoul National University College of Medicine, KoreaCVAbstract
Jong-Seo LeeES05-2Technical aspect of manufacturing CAR T cell productAbClon Inc., KoreaCV
Jae Won YooES05-3Managing adverse events of CAR T cell therapyThe Catholic University of Korea, KoreaCVAbstract
Junshik HongES06-1Prognostication in MPNs (including mutation abnormalities)Seoul National University Hospital, KoreaCVAbstract
Sung-Eun LeeES06-2Novel Therapeutics for MF (including cyotpenic myelofibrosis)The Catholic University of Korea, KoreaCVAbstract
Seugyun YoonES06-3Novel Therapeutics for ET/PVSoonchunhyang University Seoul Hospital, KoreaCVAbstract
Andreas HocchausASCIMINIB, new paradigm treatment option in CML for patients who were previously treated with 2 or more TKIsJena University Hospital, GermanyCVAbstract
Georg LenzUnmet need in 1L DLBCL and POLARIX trialUniversity Hospital in Münster, GermanyCVAbstract
Kevin SongMaintenance treatment post autotransplant for multiple myelomaVancouver General Hospital, CanadaCVAbstract
Kohei HosokawaRecent advances in the pathogenesis and treatment of aplastic anemiaKanazawa University, JapanCVAbstract
Martin BornhaeuserValue of intensive therapy in high-risk AMLUniversity Hospital Carl Gustav Carus Dresden, GermanyCVAbstract
Paolo GhiaWhen and whom to start treatment of CLL patients and how to optimally manage CLL patients with ImbruvicaIRCCS Ospedale San Raffaele, ItalyCVAbstract